Myo inositol and lung cancer
A phase I study of myo-inositol for lung cancer chemoprevention.
Cancer Epidemiol Biomarkers Prev. 2006 Aug. Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E.
Department of Respiratory Medicine, British Columbia Cancer Agency, British Columbia, Canada.
A phase I, open-label, multiple dose, dose-escalation clinical study was conducted to assess the safety, tolerability, maximum tolerated dose, and potential chemopreventive effect of myo-inositol in smokers with bronchial dysplasia. Smokers between 40 and 74 years of age with more than 30 pack-years of smoking history and one or more sites of bronchial dysplasia were enrolled. A dose escalation study ranging from 12 to 30 g/d of myo-inositol for a month was first conducted in 16 subjects to determine the maximum tolerated dose. Ten new subjects were then enrolled to take the maximum tolerated dose for 3 months. The potential chemopreventive effect of myo-inositol was estimated by repeat autofluorescence bronchoscopy and biopsy. The maximum tolerated dose was found to be 18 grams per day. Side effects, when present, were mild and mainly gastrointestinal in nature. A significant increase in the rate of regression of preexisting dysplastic lesions was observed versus placebo (91% versus 48%). A statistically significant reduction in systolic and diastolic blood pressures by an average of 10 mm Hg was observed after taking 18 g/d of myo-inositol for a month or more. Myo-Inositol in a daily dose of 18 g orally for 3 months is safe and well tolerated.